- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
8
Companies which are potentially undervalued and in an acceptable financial position.
8 companies
Hugel
Market Cap: ₩2.5t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩240,500.00
7D
-5.7%
1Y
-30.7%
Dong-A Socio Holdings
Market Cap: ₩550.2b
Engages in the pharmaceutical business in South Korea.
A000640
₩82,500.00
7D
-0.4%
1Y
-30.1%
Dong-A ST
Market Cap: ₩338.3b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩36,300.00
7D
3.0%
1Y
-24.2%
Daewoong Pharmaceutical
Market Cap: ₩1.5t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩133,100.00
7D
0.5%
1Y
-17.6%
PharmaResearch
Market Cap: ₩3.2t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩319,500.00
7D
-6.3%
1Y
-43.0%
Hanmi Pharm
Market Cap: ₩5.1t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩389,500.00
7D
-15.6%
1Y
36.4%
Medy-Tox
Market Cap: ₩463.4b
Operates as a biopharmaceutical company in South Korea.
A086900
₩72,700.00
7D
-8.1%
1Y
-55.4%
ST PharmLtd
Market Cap: ₩2.5t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩123,600.00
7D
-5.3%
1Y
48.4%